Bilateral subthalamic nucleus stimulation in advanced Parkinson's disease: five year follow-up.
Identifieur interne : 000C21 ( PubMed/Corpus ); précédent : 000C20; suivant : 000C22Bilateral subthalamic nucleus stimulation in advanced Parkinson's disease: five year follow-up.
Auteurs : Hélène Gervais-Bernard ; Jing Xie-Brustolin ; Patrick Mertens ; Gustavo Polo ; Hélène Klinger ; Dario Adamec ; Emmanuel Broussolle ; Stéphane ThoboisSource :
- Journal of neurology [ 1432-1459 ] ; 2009.
English descriptors
- KwdEn :
- Adult, Aged, Antiparkinson Agents (administration & dosage), Blinking (drug effects), Blinking (physiology), Deep Brain Stimulation (methods), Depressive Disorder (etiology), Disease Progression, Dose-Response Relationship, Drug, Drug Resistance, Dysarthria (etiology), Female, Follow-Up Studies, Functional Laterality (physiology), Humans, Male, Middle Aged, Outcome Assessment (Health Care) (methods), Parkinson Disease (physiopathology), Parkinson Disease (therapy), Subthalamic Nucleus (anatomy & histology), Subthalamic Nucleus (physiology), Time, Time Factors, Treatment Outcome.
- MESH :
- chemical , administration & dosage : Antiparkinson Agents.
- anatomy & histology : Subthalamic Nucleus.
- drug effects : Blinking.
- etiology : Depressive Disorder, Dysarthria.
- methods : Deep Brain Stimulation, Outcome Assessment (Health Care).
- physiology : Blinking, Functional Laterality, Subthalamic Nucleus.
- physiopathology : Parkinson Disease.
- therapy : Parkinson Disease.
- Adult, Aged, Disease Progression, Dose-Response Relationship, Drug, Drug Resistance, Female, Follow-Up Studies, Humans, Male, Middle Aged, Time, Time Factors, Treatment Outcome.
Abstract
To assess the long-term efficacy and safety of bilateral subthalamic nucleus (STN) stimulation in patients with advanced Parkinson's disease (PD).
DOI: 10.1007/s00415-009-0076-2
PubMed: 19242649
Links to Exploration step
pubmed:19242649Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Bilateral subthalamic nucleus stimulation in advanced Parkinson's disease: five year follow-up.</title>
<author><name sortKey="Gervais Bernard, Helene" sort="Gervais Bernard, Helene" uniqKey="Gervais Bernard H" first="Hélène" last="Gervais-Bernard">Hélène Gervais-Bernard</name>
<affiliation><nlm:affiliation>Claude Bernard Lyon I, Université de Lyon, Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie C, Lyon, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Xie Brustolin, Jing" sort="Xie Brustolin, Jing" uniqKey="Xie Brustolin J" first="Jing" last="Xie-Brustolin">Jing Xie-Brustolin</name>
</author>
<author><name sortKey="Mertens, Patrick" sort="Mertens, Patrick" uniqKey="Mertens P" first="Patrick" last="Mertens">Patrick Mertens</name>
</author>
<author><name sortKey="Polo, Gustavo" sort="Polo, Gustavo" uniqKey="Polo G" first="Gustavo" last="Polo">Gustavo Polo</name>
</author>
<author><name sortKey="Klinger, Helene" sort="Klinger, Helene" uniqKey="Klinger H" first="Hélène" last="Klinger">Hélène Klinger</name>
</author>
<author><name sortKey="Adamec, Dario" sort="Adamec, Dario" uniqKey="Adamec D" first="Dario" last="Adamec">Dario Adamec</name>
</author>
<author><name sortKey="Broussolle, Emmanuel" sort="Broussolle, Emmanuel" uniqKey="Broussolle E" first="Emmanuel" last="Broussolle">Emmanuel Broussolle</name>
</author>
<author><name sortKey="Thobois, Stephane" sort="Thobois, Stephane" uniqKey="Thobois S" first="Stéphane" last="Thobois">Stéphane Thobois</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2009">2009</date>
<idno type="RBID">pubmed:19242649</idno>
<idno type="pmid">19242649</idno>
<idno type="doi">10.1007/s00415-009-0076-2</idno>
<idno type="wicri:Area/PubMed/Corpus">000C21</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000C21</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Bilateral subthalamic nucleus stimulation in advanced Parkinson's disease: five year follow-up.</title>
<author><name sortKey="Gervais Bernard, Helene" sort="Gervais Bernard, Helene" uniqKey="Gervais Bernard H" first="Hélène" last="Gervais-Bernard">Hélène Gervais-Bernard</name>
<affiliation><nlm:affiliation>Claude Bernard Lyon I, Université de Lyon, Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie C, Lyon, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Xie Brustolin, Jing" sort="Xie Brustolin, Jing" uniqKey="Xie Brustolin J" first="Jing" last="Xie-Brustolin">Jing Xie-Brustolin</name>
</author>
<author><name sortKey="Mertens, Patrick" sort="Mertens, Patrick" uniqKey="Mertens P" first="Patrick" last="Mertens">Patrick Mertens</name>
</author>
<author><name sortKey="Polo, Gustavo" sort="Polo, Gustavo" uniqKey="Polo G" first="Gustavo" last="Polo">Gustavo Polo</name>
</author>
<author><name sortKey="Klinger, Helene" sort="Klinger, Helene" uniqKey="Klinger H" first="Hélène" last="Klinger">Hélène Klinger</name>
</author>
<author><name sortKey="Adamec, Dario" sort="Adamec, Dario" uniqKey="Adamec D" first="Dario" last="Adamec">Dario Adamec</name>
</author>
<author><name sortKey="Broussolle, Emmanuel" sort="Broussolle, Emmanuel" uniqKey="Broussolle E" first="Emmanuel" last="Broussolle">Emmanuel Broussolle</name>
</author>
<author><name sortKey="Thobois, Stephane" sort="Thobois, Stephane" uniqKey="Thobois S" first="Stéphane" last="Thobois">Stéphane Thobois</name>
</author>
</analytic>
<series><title level="j">Journal of neurology</title>
<idno type="eISSN">1432-1459</idno>
<imprint><date when="2009" type="published">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Antiparkinson Agents (administration & dosage)</term>
<term>Blinking (drug effects)</term>
<term>Blinking (physiology)</term>
<term>Deep Brain Stimulation (methods)</term>
<term>Depressive Disorder (etiology)</term>
<term>Disease Progression</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Resistance</term>
<term>Dysarthria (etiology)</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Functional Laterality (physiology)</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Outcome Assessment (Health Care) (methods)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Parkinson Disease (therapy)</term>
<term>Subthalamic Nucleus (anatomy & histology)</term>
<term>Subthalamic Nucleus (physiology)</term>
<term>Time</term>
<term>Time Factors</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomy & histology" xml:lang="en"><term>Subthalamic Nucleus</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Blinking</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Depressive Disorder</term>
<term>Dysarthria</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Deep Brain Stimulation</term>
<term>Outcome Assessment (Health Care)</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Blinking</term>
<term>Functional Laterality</term>
<term>Subthalamic Nucleus</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Disease Progression</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Resistance</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Time</term>
<term>Time Factors</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">To assess the long-term efficacy and safety of bilateral subthalamic nucleus (STN) stimulation in patients with advanced Parkinson's disease (PD).</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19242649</PMID>
<DateCreated><Year>2009</Year>
<Month>03</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted><Year>2009</Year>
<Month>07</Month>
<Day>14</Day>
</DateCompleted>
<DateRevised><Year>2009</Year>
<Month>03</Month>
<Day>16</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1459</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>256</Volume>
<Issue>2</Issue>
<PubDate><Year>2009</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
<Title>Journal of neurology</Title>
<ISOAbbreviation>J. Neurol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Bilateral subthalamic nucleus stimulation in advanced Parkinson's disease: five year follow-up.</ArticleTitle>
<Pagination><MedlinePgn>225-33</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-009-0076-2</ELocationID>
<Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess the long-term efficacy and safety of bilateral subthalamic nucleus (STN) stimulation in patients with advanced Parkinson's disease (PD).</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">42 consecutive patients with idiopathic PD treated with bilateral STN stimulation were enrolled. Parkinsonian status, medication intake and neuropsychological evaluation were assessed preoperatively and at 1 and 5 years postoperatively in on and off medication/on and off stimulation conditions.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">23 patients could be followed-up 5 years after surgery. In the remaining cases, 5 died, 1 could not be assessed because of device removal for infection, 1 decided not to be stimulated, and 11 were lost of follow-up (one because of a liver carcinoma and the others because they refused the formal four conditions of assessment). STN stimulation reduced the UPDRS motor score by 55 % compared to baseline in the off-medication conditions. Tremor, rigidity, bradykinesia, postural stability, and gait improved by 74 %, 66 %, 59 %, 17 % and 37 %, respectively. UPDRS part II scores were reduced by 38 %. The dopaminergic treatment daily dose was reduced by 54.4 % after surgery. Axial dopa-unresponsive signs worsened in some patients. Among the 42 initial patients we observed the following: 2 brain hemorrhages, 3 infections of the device, 2 phlebitis and 1 pulmonary embolism. In addition, 2 patients needed a repositioning of the electrode. Among the 23 patients followed at 5 years, long lasting side effects consisted in dysarthria (56 %), depression (39 %), eyelid opening apraxia (30.4 %) and apathy (4.3 %).</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our data confirm that bilateral STN stimulation is beneficial in the long-term for PD patients but does not prevent disease progression and the occurence of axial levodopa unresponsive signs in some patients.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gervais-Bernard</LastName>
<ForeName>Hélène</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Claude Bernard Lyon I, Université de Lyon, Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie C, Lyon, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Xie-Brustolin</LastName>
<ForeName>Jing</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>Mertens</LastName>
<ForeName>Patrick</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y"><LastName>Polo</LastName>
<ForeName>Gustavo</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y"><LastName>Klinger</LastName>
<ForeName>Hélène</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y"><LastName>Adamec</LastName>
<ForeName>Dario</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y"><LastName>Broussolle</LastName>
<ForeName>Emmanuel</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y"><LastName>Thobois</LastName>
<ForeName>Stéphane</ForeName>
<Initials>S</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2009</Year>
<Month>02</Month>
<Day>26</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Germany</Country>
<MedlineTA>J Neurol</MedlineTA>
<NlmUniqueID>0423161</NlmUniqueID>
<ISSNLinking>0340-5354</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001767" MajorTopicYN="N">Blinking</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D046690" MajorTopicYN="N">Deep Brain Stimulation</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004351" MajorTopicYN="N">Drug Resistance</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004401" MajorTopicYN="N">Dysarthria</DescriptorName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007839" MajorTopicYN="N">Functional Laterality</DescriptorName>
<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment (Health Care)</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020531" MajorTopicYN="N">Subthalamic Nucleus</DescriptorName>
<QualifierName UI="Q000033" MajorTopicYN="N">anatomy & histology</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013995" MajorTopicYN="N">Time</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year>
<Month>03</Month>
<Day>26</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2008</Year>
<Month>07</Month>
<Day>23</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2008</Year>
<Month>07</Month>
<Day>07</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2009</Year>
<Month>2</Month>
<Day>27</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2009</Year>
<Month>2</Month>
<Day>27</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2009</Year>
<Month>7</Month>
<Day>15</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">19242649</ArticleId>
<ArticleId IdType="doi">10.1007/s00415-009-0076-2</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C21 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000C21 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:19242649 |texte= Bilateral subthalamic nucleus stimulation in advanced Parkinson's disease: five year follow-up. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:19242649" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a ParkinsonFranceV1
This area was generated with Dilib version V0.6.29. |